DarioHealth Corp. announced a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024. The employer, a leader in environmental services, selected Dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a GLP-1 medication.

Dario's proven ability to drive sustainable behavior change is key to helping employees achieve successful outcomes while taking a GLP-1, as research shows that 68% of people stop taking these medications within a year, putting them at high-risk of regaining the weight lost. Dario is proven to drive sustainable behavior change using billions of data insights gathered from a decade of consumer engagement to deliver highly personalized journeys that keep members engaged over time. The enhanced engagement capabilities inherited from the Company's acquisition of Twill bolster Dario's ability to engage members for long-term success with enhanced behavioral support.